- Home
- MBBC vs NRXP Comparison
MBBC vs NRXP Comparison
Compare MBBC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- NRXP
- Stock Information
- Founded
- MBBC 1902
- NRXP 2015
- Country
- MBBC United States
- NRXP United States
- Employees
- MBBC N/A
- NRXP N/A
- Industry
- MBBC Banks
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- NRXP Health Care
- Exchange
- MBBC Nasdaq
- NRXP Nasdaq
- Market Cap
- MBBC 29.3M
- NRXP 32.6M
- IPO Year
- MBBC N/A
- NRXP N/A
- Fundamental
- Price
- MBBC $10.00
- NRXP $3.34
- Analyst Decision
- MBBC
- NRXP Strong Buy
- Analyst Count
- MBBC 0
- NRXP 4
- Target Price
- MBBC N/A
- NRXP $28.50
- AVG Volume (30 Days)
- MBBC 10.3K
- NRXP 240.0K
- Earning Date
- MBBC 08-22-2025
- NRXP 08-13-2025
- Dividend Yield
- MBBC N/A
- NRXP N/A
- EPS Growth
- MBBC 103.56
- NRXP N/A
- EPS
- MBBC 0.22
- NRXP N/A
- Revenue
- MBBC $6,591,743.00
- NRXP N/A
- Revenue This Year
- MBBC N/A
- NRXP N/A
- Revenue Next Year
- MBBC N/A
- NRXP N/A
- P/E Ratio
- MBBC $45.31
- NRXP N/A
- Revenue Growth
- MBBC N/A
- NRXP N/A
- 52 Week Low
- MBBC $6.38
- NRXP $1.10
- 52 Week High
- MBBC $12.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- NRXP 60.08
- Support Level
- MBBC N/A
- NRXP $2.90
- Resistance Level
- MBBC N/A
- NRXP $3.53
- Average True Range (ATR)
- MBBC 0.00
- NRXP 0.19
- MACD
- MBBC 0.00
- NRXP -0.03
- Stochastic Oscillator
- MBBC 0.00
- NRXP 84.13
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.